|
|
| | 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Basic information |
| Product Name: | 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE | | Synonyms: | Benz[7,8]indolizino[2,3-b]quinoxaline,5,6-dihydro-2,3-dimethoxy-6,6-dimethyl-;5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE;YM 90709;2,3-Dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline;YM 90709;YM90709;YM-90709;YM-90709,GM-CSF,inhibit,Inhibitor,Interleukin Related,IL-5,eosinophils,IL-5R,JAK2 | | CAS: | 163769-88-8 | | MF: | C22H21N3O2 | | MW: | 359.42 | | EINECS: | | | Product Categories: | API | | Mol File: | 163769-88-8.mol | ![5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Structure](CAS/GIF/163769-88-8.gif) |
| | 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Chemical Properties |
| Boiling point | 579.6±50.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMF: 10 mg/ml; DMSO: 20 mg/ml; Ethanol: 2 mg/ml | | form | A crystalline solid | | pka | 2.74±0.40(Predicted) | | color | Brown to orange |
| | 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Usage And Synthesis |
| Description | YM-90709 is a competitive antagonist of the interleukin-5 (IL-5) receptor that has IC50 values of 1 and 0.57 μM for peripheral human eosinophils and eosinophilic HL-60 clone 15 cells, respectively, in a radioligand binding assay. It inhibits IL-5-induced eosinophil survival (IC50 = 0.45 μM) and JAK2 phosphorylation in vitro. YM-90709 inhibits eosinophil and lymphocyte infiltration (ED50s = 0.32 and 0.12 mg/kg, respectively) into the brochoalveolar lavage fluid (BALF) of rats and eosinophil infiltration (ED50 = 0.05 mg/kg) into the BALF of mice in models of airway inflammation. | | Uses | YM 90709, is an interleukin-5 receptor antagonist. | | Definition | ChEBI: LSM-2128 is a quinoxaline derivative. | | Biological Activity | Novel, selective inhibitor of interleukin-5 (IL-5) binding to its receptor (IC 50 = 0.45-1 mM). Inhibits IL-5-prolonged eosinophil survival and IL-5-induced tyrosine phosphorylation of JAK2 without inhibiting GM-CSF-mediated effects. In vivo, inhibits antigen-induced eosinophil and lymphocyte recruitment in rat airways, without affecting peripheral blood or bone marrow leukocytes. |
| | 5,6-DIHYDRO-2,3-DIMETHOXY-6,6-DIMETHYLBENZ[7,8]INDOLIZINO[2,3-B]QUINOXALINE Preparation Products And Raw materials |
|